Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTE-X19 in MRD Positive B-ALL
NCT06144606Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2023
- Primary completion
- Jul 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Moffitt Cancer Center. Started Dec 2023; status: recruiting.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06144606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144606.